Latest Transformation News

Codeifai Limited has raised $2.35 million through a share placement to fund key acquisitions and expand its footprint in quantum computing and AI. The move signals a strategic push towards U.S. market engagement and commercialisation of cutting-edge technology.

AdNeo Limited reports sustained positive cash flow and strong contract wins, advancing its strategic acquisition of Learnt Global ahead of schedule while securing $5.5 million in new capital.

Forrestania Resources has voluntarily suspended trading on the ASX as it prepares to announce a significant acquisition, signaling a potentially transformative move for the mining company.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.

Bass Oil reported steady oil production and a significant cash reserve increase in the June quarter, while strategically acquiring the Vanessa gas field to pivot towards gas production.

TMK Energy has commenced drilling its seventh pilot well at the Gurvantes XXXV Coal Seam Gas Project, reporting positive reservoir pressure tests and advancing partnerships to fast-track development.

AnteoTech advances its battery technology with a new US joint development agreement and achieves significant performance milestones, while restructuring to sharpen its commercial focus.

Kingsrose Mining advances its Finnmark exploration with promising new magnetic and conductive anomalies, while BHP withdraws from Central Finland to concentrate resources. Leadership changes and a robust cash position set the stage for an active year ahead.

Odyssey Gold Limited has advanced its Tuckanarra Gold Project with a new mill access agreement, ongoing drilling, and a $4 million capital raise, positioning the company for a potential resource upgrade.

Core Lithium has repositioned its Finniss Lithium Project as a low-cost underground operation with a 20-year mine life, slashing operating costs by a third and boosting production capacity. The company is advancing strategic funding while unlocking flexibility through a key offtake agreement termination.

Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.

Lark Distilling Co. reported a robust 12% increase in FY25 net sales to $15.6 million, underpinned by a completed brand restage and a major distillery upgrade at Pontville. Despite some export and B2B softness, the company’s strong cash position and strategic investments position it well for growth.